Ibrutinib is a first-in-class oral irreversible inhibitor of Bruton Tyrosine Kinase (BTK), a critical enzyme in the B-cell receptor signaling cascade, and is highly effective in the treatment of CLL, MCL and Waldenstrom’s macroglobulinaemia. Here, BTK is linked to Waldenstrom macroglobulinemia.